SAN FRANCISCO–(BUSINESS WIRE)–#classaction–Berman Tabacco, (www.bermantabacco.com), a national law firm representing investors is investigating possible securities law violations involving Omnicell, Inc. (“Omnicell” or the “Company”) (Nasdaq: OMCL).
Omnicell provides medication and supply dispensing automation solutions, central pharmacy automation solutions, analytics software, and medication adherence solutions which are sold in its principal market, which is the healthcare industry. The Company is based in Mountain View, California.
On July 11, 2019, Bloomberg reported in an article titled “Omnicell Drops After Cautious Mention at Glasshouse Research” that shares of Omnicell had fallen as much as 7.2% after GlassHouse research “said the shares may have 59% downside due to accounting issues at the company.” According to Bloomberg, GlassHouse alleges, among other things, that the Company is “prematurely recognizing revenue and failing to write-off legacy inventory.”
If you would like more information regarding this investigation, or if you wish to share information about the investigation, you may can find more information here: https://www.bermantabacco.com/case/canntrust-holdings-inc/
Berman Tabacco is a national law firm representing institutions and individuals in lawsuits, seeking to recoup losses caused by violations of securities and antitrust laws. The firm has 37 lawyers in Boston and San Francisco.
This notice may constitute attorney advertising.
Contacts
Chowning Poppler
[email protected]
(800) 516-9926 or (415) 433-3200
